vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and Purple Innovation, Inc. (PRPL). Click either name above to swap in a different company.
Purple Innovation, Inc. is the larger business by last-quarter revenue ($140.7M vs $94.9M, roughly 1.5× DYNAVAX TECHNOLOGIES CORP). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs -2.3%, a 30.7% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 9.1%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $-7.8M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 8.3%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
Purple Carrot is a Needham, Massachusetts-based, and 100% plant-based meal kit company. Founded by Andy Levitt, it offers both prepared meals as well as meal kits to subscribers weekly. As stated in a 2022 article in Cosmopolitan, “each Purple Carrot meal kit results in 72% less carbon being released into the atmosphere as compared to the standard American meal.”
DVAX vs PRPL — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $140.7M |
| Net Profit | $26.9M | $-3.2M |
| Gross Margin | — | 41.9% |
| Operating Margin | 22.4% | -1.6% |
| Net Margin | 28.4% | -2.3% |
| Revenue YoY | 17.7% | 9.1% |
| Net Profit YoY | 53.0% | 62.1% |
| EPS (diluted) | $0.21 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $140.7M | ||
| Q3 25 | $94.9M | $118.8M | ||
| Q2 25 | $95.4M | $105.1M | ||
| Q1 25 | $68.2M | $104.2M | ||
| Q4 24 | $72.0M | $129.0M | ||
| Q3 24 | $80.6M | $118.6M | ||
| Q2 24 | $73.8M | $120.3M | ||
| Q1 24 | $50.8M | $120.0M |
| Q4 25 | — | $-3.2M | ||
| Q3 25 | $26.9M | $-11.7M | ||
| Q2 25 | $18.7M | $-17.3M | ||
| Q1 25 | $-96.1M | $-19.1M | ||
| Q4 24 | $7.0M | $-8.5M | ||
| Q3 24 | $17.6M | $-39.2M | ||
| Q2 24 | $11.4M | $27.0K | ||
| Q1 24 | $-8.7M | $-50.2M |
| Q4 25 | — | 41.9% | ||
| Q3 25 | — | 42.8% | ||
| Q2 25 | — | 35.9% | ||
| Q1 25 | — | 39.4% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 40.7% | ||
| Q1 24 | — | 34.8% |
| Q4 25 | — | -1.6% | ||
| Q3 25 | 22.4% | -10.2% | ||
| Q2 25 | 15.1% | -13.5% | ||
| Q1 25 | -34.7% | -13.9% | ||
| Q4 24 | -2.3% | -6.0% | ||
| Q3 24 | 12.5% | -39.5% | ||
| Q2 24 | 7.0% | -12.1% | ||
| Q1 24 | -35.0% | -19.3% |
| Q4 25 | — | -2.3% | ||
| Q3 25 | 28.4% | -9.9% | ||
| Q2 25 | 19.6% | -16.5% | ||
| Q1 25 | -141.0% | -18.4% | ||
| Q4 24 | 9.8% | -6.6% | ||
| Q3 24 | 21.8% | -33.1% | ||
| Q2 24 | 15.4% | 0.0% | ||
| Q1 24 | -17.2% | -41.8% |
| Q4 25 | — | $0.03 | ||
| Q3 25 | $0.21 | $0.11 | ||
| Q2 25 | $0.14 | $0.16 | ||
| Q1 25 | $-0.77 | $0.18 | ||
| Q4 24 | $0.07 | $0.08 | ||
| Q3 24 | $0.12 | $0.36 | ||
| Q2 24 | $0.08 | $0.00 | ||
| Q1 24 | $-0.07 | $0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $24.3M |
| Total DebtLower is stronger | — | $126.7M |
| Stockholders' EquityBook value | $534.1M | $-29.7M |
| Total Assets | $946.5M | $296.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.3M | ||
| Q3 25 | $160.2M | $32.4M | ||
| Q2 25 | $99.1M | $34.2M | ||
| Q1 25 | $51.7M | $21.6M | ||
| Q4 24 | $95.9M | $29.0M | ||
| Q3 24 | $119.3M | $23.4M | ||
| Q2 24 | $112.5M | $23.4M | ||
| Q1 24 | $132.0M | $34.5M |
| Q4 25 | — | $126.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-29.7M | ||
| Q3 25 | $534.1M | $-26.9M | ||
| Q2 25 | $494.2M | $-15.6M | ||
| Q1 25 | $530.9M | $1.3M | ||
| Q4 24 | $596.8M | $20.2M | ||
| Q3 24 | $681.4M | $28.0M | ||
| Q2 24 | $642.8M | $66.4M | ||
| Q1 24 | $618.5M | $65.5M |
| Q4 25 | — | $296.3M | ||
| Q3 25 | $946.5M | $302.1M | ||
| Q2 25 | $918.4M | $303.8M | ||
| Q1 25 | $945.9M | $293.8M | ||
| Q4 24 | $986.3M | $307.8M | ||
| Q3 24 | $1.1B | $309.3M | ||
| Q2 24 | $1.0B | $362.1M | ||
| Q1 24 | $986.6M | $382.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $-5.8M |
| Free Cash FlowOCF − Capex | $32.6M | $-7.8M |
| FCF MarginFCF / Revenue | 34.4% | -5.5% |
| Capex IntensityCapex / Revenue | 1.3% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $-41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-5.8M | ||
| Q3 25 | $33.8M | $-968.0K | ||
| Q2 25 | $23.4M | $-4.0M | ||
| Q1 25 | $-19.6M | $-23.1M | ||
| Q4 24 | $53.0M | $6.8M | ||
| Q3 24 | $19.5M | $1.1M | ||
| Q2 24 | $10.7M | $-8.9M | ||
| Q1 24 | $-16.7M | $-16.8M |
| Q4 25 | — | $-7.8M | ||
| Q3 25 | $32.6M | $-1.8M | ||
| Q2 25 | $22.0M | $-7.0M | ||
| Q1 25 | $-23.6M | $-25.3M | ||
| Q4 24 | $49.5M | $5.7M | ||
| Q3 24 | $18.1M | $101.0K | ||
| Q2 24 | $9.9M | $-11.0M | ||
| Q1 24 | $-17.4M | $-19.9M |
| Q4 25 | — | -5.5% | ||
| Q3 25 | 34.4% | -1.5% | ||
| Q2 25 | 23.0% | -6.6% | ||
| Q1 25 | -34.6% | -24.3% | ||
| Q4 24 | 68.8% | 4.4% | ||
| Q3 24 | 22.5% | 0.1% | ||
| Q2 24 | 13.5% | -9.2% | ||
| Q1 24 | -34.3% | -16.5% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | 1.3% | 0.7% | ||
| Q2 25 | 1.5% | 2.8% | ||
| Q1 25 | 5.8% | 2.2% | ||
| Q4 24 | 4.8% | 0.8% | ||
| Q3 24 | 1.7% | 0.9% | ||
| Q2 24 | 1.1% | 1.7% | ||
| Q1 24 | 1.5% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | -330.22× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
